Please assess the completion status of the following clinical trial:

Trial Title: High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed nasopharyngeal cancer~  * Stage II-IVB~ * Newly diagnosed~* No distant metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* WBC at least 3,000/mm\^3~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 8 g/dL~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2.5 times ULN~* AST no greater than 2.5 times ULN~Renal~* Creatinine no greater than 1.5 mg/dL~* Creatinine clearance at least 60 mL/min~* Calcium no greater than 11.5 mg/dL~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Medically able to tolerate a definitive course of radiotherapy and the necessary immobilization~* No other active malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for this diagnosis~* More than 3 years since other prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy for this diagnosis~* More than 3 years since other prior radiotherapy~* No prior radiotherapy to the head and neck region~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- High-Dose Radiation Therapy Plus Chemotherapy (Type: EXPERIMENTAL): Phase I~* Radiotherapy: Patients receive radiotherapy once daily 5 days a week for 6 weeks beginning on day 1.~* Concurrent chemotherapy: Patients receive cisplatin IV over 20-30 minutes on days 1-5 and 22-26.~* Adjuvant chemotherapy: Approximately 2-5 weeks after the completion of radiotherapy, patients receive fluorouracil IV continuously on days 1-4 and cisplatin IV over 20-30 minutes on days 1-5 and 22-26. Treatment repeats every 28 days for 3 courses in the absence of disease progression or unacceptable toxicity. In the absence of dose-limiting toxicity in 1 whole cohort of patients, study proceeds to phase II. Phase II~* Patients are treated as in phase I. Patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 3 years, and then annually thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).